Role of mast cells in fibrosis of classical Hodgkin lymphoma

International Journal of Immunopathology and Pharmacology

Volumn 29, Issue 4, 2016, Pages 603-611

  Nakayama, Shoko ^a   Yokote, Taiji ^a   Hiraoka, Nobuya ^a   Nishiwaki, Uta ^a   Hanafusa, Toshiaki ^a   Nishimura, Yasuichiro ^a   Tsuji, Motomu ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Classical Hodgkin lymphoma; IL 13; Mast cell; Stem cell factor; Transforming growth factor (TGF)

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 3; STEM CELL FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; IL3 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL INFILTRATION; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FIBROGENESIS; FIBROSIS; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MALE; MAST CELL; MIDDLE AGED; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; VERY ELDERLY; YOUNG ADULT; HODGKIN DISEASE; METABOLISM; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FIBROSIS; HODGKIN DISEASE; HUMANS; INTERLEUKIN-13; INTERLEUKIN-3; LYMPH NODES; MALE; MAST CELLS; MIDDLE AGED; REED-STERNBERG CELLS; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 85016923334     PISSN: 03946320     EISSN: 20587384     Source Type: Journal    
DOI: 10.1177/0394632016644447     Document Type: Article

References (36)

1. Stein H, Poppema S, Delsol G, et al. (2008) Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al. (eds) World Health Organization classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press, pp. 322–334.
2. Gruss HJ, Pinto A, Duyster J, et al. (1997) Hodgkin’s disease: A tumor with disturbed immunological pathways. Immunology Today 18: 156–163.
3. Skinnider BF and Mak TW (2002) The role of cytokines in classical Hodgkin lymphoma. Blood 99: 4283–4297.
4. Newcom SR and Gu L (1995) Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin’s disease. Journal of Clinical Pathology 48: 160–163.
5. Kadin ME, Agnarsson BA, Ellingsworth LR, et al. (1990) Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin’s disease. American Journal of Pathology 136: 1209–1214.
6. Sime PJ and O’Reilly KM (2001) Fibrosis of the lung and other tissues: New concepts in pathogenesis and treatment. Clinical Immunology 99: 308–319.
7. Wynn TA (2004). Fibrotic disease and the T(H)1/T(H)2 paradigm. Nature Reviews Immunology 4: 583–594.
8. O’Reilly S (2013) Role of interleukin-13 in fibrosis, particularly systemic sclerosis. Biofactors 39: 593–596.
9. Ohshima K, Akaiwa M, Umeshita R, et al. (2001) Interleukin-13 and interleukin-13 receptor in Hodgkin’s disease: Possible autocrine mechanism and involvement in fibrosis. Histopathology 38: 368–375.
10. Li Y, Zhou L, Liu F, Peng Y, et al. (2010) Mast cell infiltration is involved in renal interstitial fibrosis in a rat model of protein-overload nephropathy. Kidney and Blood Pressure Research 33: 240–248.
11. Li Y, Liu FY, Peng YM, et al. (2007) Mast cell, a promising therapeutic target in tubulointerstitial fibrosis. Medical Hypotheses 69: 99–103.
12. Takeuchi M, Sato Y, Ohno K, et al. (2014) T helper 2 and regulatory T-cell cytokine production by mast cells: A key factor in the pathogenesis of IgG4-related disease. Modern Pathology 27: 1126–1136.
13. Nilsson G, Butterfield JH, Nilsson K, et al. (1994) Stem cell factor is a chemotactic factor for human mast cells. Journal of Immunology 153: 3717–3723.
14. Collington SJ, Williams TJ and Weller CL (2011) Mechanisms underlying the localisation of mast cells in tissues. Trends in Immunology 32: 478–485.
15. Kritas SK, Saggini A, Cerulli G, et al. (2014) Interrelationship between IL-3 and mast cells. Journal of Biological Regulators & Homeostatic Agents 28: 17–21.
16. Kaur D, Hollins F, Woodman L, et al. (2006) Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression. Allergy 61: 1047–1053.
17. Gri G, Frossi B, D’Inca F, et al. (2012) Mast cell: An emerging partner in immune interaction. Frontiers in Immunology 3: 120.
18. Gruber BL (2003). Mast cells in the pathogenesis of fibrosis. Current Rheumatology Reports 5: 147–53.
19. Lantz CS, Boesiger J, Song CH, et al. (1998) Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature 392: 90–93.
20. Lennartsson J and Rönnstrand L (2012) Stem cell factor receptor/c-Kit: From basic science to clinical implications. Physiological Reviews 92: 1619–1649.
21. Smith MA, Court EL and Smith JG (2001) Stem cell factor: Laboratory and clinical aspects. Blood Reviews 15: 191–197.
22. Martinho O, Gonçalves A, Moreira MA, et al. (2008) KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops. Gynecologic Oncology 111: 350–355.
23. Horstmann M, Hennenlotter J, Geiger LM, et al. (2012) Evaluation of the KIT/stem cell factor axis in renal tumors. Anticancer Research 32: 4339–4345.
24. Krystal GW, Hines SJ and Organ CP (1996) Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Research 56: 370–376.
25. Yasuda A, Sawai H, Takahashi H, et al. (2006) The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Molecular Cancer 5: 46.
26. Hart PH (2001) Regulation of the inflammatory response in asthma by mast cell products. Immunology and Cell Biology 79: 149–153.
27. Wills-Karp M (2004) Interleukin-13 in asthma pathogenesis. Immunological Reviews 202: 175–190.
28. Keresztes K, Szollosi Z, Simon Z, et al. (2007) Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin’s lymphoma. Pathology & Oncology Research 13: 237–242.
29. Andersen MD, Kamper P, Nielsen PS, et al. (2016) Tumour-associated mast cells in classical Hodgkin’s lymphoma: Correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome. European Journal of Haematology 96: 252–259.
30. Glimelius I, Rubin J, Rostgaard K, et al. (2011) Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin’s lymphoma–a population-based study. European Journal of Haematology 87: 208–216.
31. Molin D, Edström A, Glimelius I, et al. (2002) Mast cell infiltration correlates with poor prognosis in Hodgkin’s lymphoma. British Journal of Haematology 119:122–124.
32. Mizuno H, Nakayama T, Miyata Y, et al. (2012) Mast cells promote the growth of Hodgkin’s lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib. Leukemia 26: 2269–2276.
33. Elpek GO, Gelen T, Aksoy NH, et al. (2001) The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. Journal of Clinical Pathology 54: 940–944.
34. Huang B, Lei Z, Zhang GM, et al. (2008) SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112: 1269–1279.
35. Zhang W, Wu K, He W, et al. (2010) Transforming growth factor beta 1 plays an important role in inducing CD4(+)CD25(+)forhead box P3(+) regulatory T cells by mast cells. Clinical & Experimental Immunology 161: 490–496.
36. Sugiyama D, Nishikawa H, Maeda Y, et al. (2013) Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proceedings of the National Academy of Sciences of the United States of America 110: 17945–17950.